p.110 抽出テキスト

603. Geske JB, Cullen MW, Sorajja P, Ommen SR, Nishimura RA. Assessment of left ventricular outflow gradient: hypertrophic cardiomyopathy versus aortic valvular stenosis. JACC Cardiovasc Interv 2012;5:675–681. https://doi.org/10.1016/j.jcin.2012.01.026 604. Rudolph A, Abdel-Aty H, Bohl S, Boye P, Zagrosek A, Dietz R, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 2009;53: 284–291. https://doi.org/10.1016/j.jacc.2008.08.064 605. Moon JCC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;43:2260–2264. https://doi.org/10. 1016/j.jacc.2004.03.035 606. Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol 2009;54:242–249. https://doi.org/10.1016/j.jacc.2009.04.026 607. White RD, Obuchowski NA, Gunawardena S, Lipchik EO, Lever HM, Van Dyke CW, et al. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: presurgical and postsurgical evaluation by computed tomography magnetic resonance imaging. Am J Card Imaging 1996;10:1–13. 608. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107:2227–2232. https://doi. org/10.1161/01.CIR.0000066323.15244.54 609. Murphy SL, Anderson JH, Kapplinger JD, Kruisselbrink TM, Gersh BJ, Ommen SR, et al. Evaluation of the Mayo Clinic phenotype-based genotype predictor score in patients with clinically diagnosed hypertrophic cardiomyopathy. J Cardiovasc Transl Res 2016;9: 153–161. https://doi.org/10.1007/s12265-016-9681-5 610. Gruner C, Ivanov J, Care M, Williams L, Moravsky G, Yang H, et al. Toronto hypertrophic cardiomyopathy genotype score for prediction of a positive genotype in hypertrophic cardiomyopathy. Circ Cardiovasc Genet 2013;6:19–26. https://doi.org/ 10.1161/CIRCGENETICS.112.963363 611. Ingles J, Burns C, Bagnall RD, Lam L, Yeates L, Sarina T, et al. Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications. Circ Cardiovasc Genet 2017;10:e001620. https://doi.org/10.1161/CIRCGENETICS.116.001620 612. Ko C, Arscott P, Concannon M, Saberi S, Day SM, Yashar BM, et al. Genetic testing impacts the utility of prospective familial screening in hypertrophic cardiomyopathy through identification of a nonfamilial subgroup. Genet Med 2018;20:69–75. https:// doi.org/10.1038/gim.2017.79 613. Anan R, Shono H, Kisanuki A, Arima S, Nakao S, Tanaka H. Patients with familial hypertrophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favorable prognosis. Circulation 1998;98:391–397. https://doi.org/10.1161/01.CIR.98.5.391 614. Elliott P, Baker R, Pasquale F, Quarta G, Ebrahim H, Mehta AB, et al. Prevalence of Anderson–Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson–Fabry Disease survey. Heart 2011;97:1957–1960. https://doi. org/10.1136/heartjnl-2011-300364 615. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009;10:165–193. https://doi.org/10.1093/ejechocard/ jep007 616. Kubo T, Gimeno JR, Bahl A, Steffensen U, Steffensen M, Osman E, et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol 2007;49:2419–2426. https://doi.org/10.1016/j.jacc.2007. 02.061 617. Biagini E, Spirito P, Rocchi G, Ferlito M, Rosmini S, Lai F, et al. Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol 2009;104:1727–1731. https://doi.org/10.1016/j.amjcard.2009.07.057 618. Geske JB, Sorajja P, Nishimura RA, Ommen SR. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation 2007;116:2702–2708. https://doi.org/10.1161/CIRCULATIONAHA. 107.698985 619. Kitaoka H, Kubo T, Okawa M, Takenaka N, Sakamoto C, Baba Y, et al. Tissue doppler imaging and plasma BNP levels to assess the prognosis in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2011;24:1020–1025. https://doi.org/10.1016/ j.echo.2011.05.009 620. Ha J-W, Cho J-R, Kim J-M, Ahn J-A, Choi E-Y, Kang S-M, et al. Tissue Doppler-derived indices predict exercise capacity in patients with apical hypertrophic cardiomyopathy. Chest 2005;128:3428–3433. https://doi.org/10.1378/chest.128.5.3428 621. Spoladore R, Maron MS, D’Amato R, Camici PG, Olivotto I. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J 2012;33:1724–1733. https://doi.org/10.1093/eurheartj/ehs150 622. Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020;396:759–769. https://doi.org/10.1016/S0140-6736(20)31792-X 623. Dybro AM, Rasmussen TB, Nielsen RR, Ladefoged BT, Andersen MJ, Jensen MK, et al. Effects of metoprolol on exercise hemodynamics in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2022;79:1565–1575. https://doi.org/10. 1016/j.jacc.2022.02.024 624. Wigle ED, Auger P, Marquis Y. Muscular subaortic stenosis. The direct relation between the intraventricular pressure difference and the left ventricular ejection time. Circulation 1967;36:36–44. https://doi.org/10.1161/01.CIR.36.1.36 625. Wigle ED, Henderson M, Rakowski H, Wilansky S. Muscular (hypertrophic) subaortic stenosis (hypertrophic obstructive cardiomyopathy): the evidence for true obstruction to left ventricular outflow. Postgrad Med J 1986;62:531–536. https://doi.org/10. 1136/pgmj.62.728.531 626. Stauffer JC, Ruiz V, Morard JD. Subaortic obstruction after sildenafil in a patient with hypertrophic cardiomyopathy. N Engl J Med 1999;341:700–701. https://doi.org/10. 1056/NEJM199908263410916 627. Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr, Morrow AG. Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients. Circulation 1964;30(Suppl 4):3–119. https://doi.org/10.1161/01.cir.29.5s4.iv-3 628. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104: 2517–2524. https://doi.org/10.1161/hc4601.097997 629. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33:2719–2747. https://doi.org/10.1093/eurheartj/ehs253 630. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery; Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, et al. Guidelines for the management of atrial fibrillation: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31: 2369–2429. https://doi.org/10.1093/eurheartj/ehq278 631. Dybro AM, Rasmussen TB, Nielsen RR, Andersen MJ, Jensen MK, Poulsen SH. Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2021;78:2505–2517. https://doi.org/10.1016/j.jacc.2021.07. 065 632. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:1251–1258. https://doi.org/10.1016/j.jacc.2005.01. 012 633. Sherrid MV, Shetty A, Winson G, Kim B, Musat D, Alviar CL, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil. Circ Heart Fail 2013;6:694–702. https://doi. org/10.1161/CIRCHEARTFAILURE.112.000122 634. O’Connor MJ, Miller K, Shaddy RE, Lin KY, Hanna BD, Ravishankar C, et al. Disopyramide use in infants and children with hypertrophic cardiomyopathy. Cardiol Young 2018;28:530–535. https://doi.org/10.1017/S1047951117002384 635. Adler A, Fourey D, Weissler-Snir A, Hindieh W, Chan RH, Gollob MH, et al. Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients. J Am Heart Assoc 2017;6:e005152. https://doi.org/10.1161/JAHA.116.005152 636. Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981;64:437–441. https://doi. org/10.1161/01.CIR.64.3.437 637. Rosing DR, Kent KM, Maron BJ, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation 1979;60:1208–1213. https://doi.org/10.1161/ 01.CIR.60.6.1208 638. Bonow RO, Rosing DR, Epstein SE. The acute and chronic effects of verapamil on left ventricular function in patients with hypertrophic cardiomyopathy. Eur Heart J 1983; 4(Suppl F):57–65. https://doi.org/10.1093/eurheartj/4.suppl_F.57 639. Spicer RL, Rocchini AP, Crowley DC, Vasiliades J, Rosenthal A. Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy. Circulation 1983;67:413–420. https://doi.org/10.1161/01.CIR.67.2.413 640. Rosing DR, Idanpaan-Heikkila U, Maron BJ, Bonow RO, Epstein SE. Use of calciumchannel blocking drugs in hypertrophic cardiomyopathy. Am J Cardiol 1985;55: 185B–195B. https://doi.org/10.1016/0002-9149(85)90630-7 641. Toshima H, Koga Y, Nagata H, Toyomasu K, Itaya K, Matoba T. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study. Jpn Heart J 1986;27:701–715. https://doi.org/10.1536/ ihj.27.701 642. Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol 2022;80:95–108. https://doi.org/10.1016/j.jacc.2022. 04.048 643. Desai MY, Owens A, Geske JB, Wolski K, Saberi S, Wang A, et al. Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 weeks. Circulation 2023;147:850–863. https://doi.org/10.1161/CIRCULATIONAHA.122.062534 Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026